ReviewBMC medicine2015
PCSK9 inhibition: the way forward in the treatment of dyslipidemia.
Review in BMC medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOMEDiabetes & vascular disease researchTrial
- MicroRNA-30c analog C2 decreases plasma cholesterol and atherosclerosis without causing liver injury in preclinical studies.Nature communications · 2026Article
- Therapeutic precision gene editing of cholesterol pathways as a gene therapy strategy for cardiovascular disease.Gene therapy · 2026Review
- Mendelian randomization analysis identifies druggable genes and drugs repurposing for chronic obstructive pulmonary disease.Frontiers in cellular and infection microbiology · 2024Article
- Synthesis of Novel MicroRNA-30c Analogs to Reduce Apolipoprotein B Secretion in Human Hepatoma Cells.Bio-protocol · 2022Article
- Therapeutic RNA-silencing oligonucleotides in metabolic diseases.Nature reviews. Drug discovery · 2022Review
- Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis.Journal of the American Heart Association · 2022Review
- New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease.European cardiology · 2020Review
- Helper-dependent adenovirus-mediated gene transfer of a secreted LDL receptor/transferrin chimeric protein reduces aortic atherosclerosis in LDL receptor-deficient mice.Gene therapy · 2019Article
- The effect of chronic kidney disease on lipid metabolism.International urology and nephrology · 2019Review
- Management of Statin Intolerance in 2018: Still More Questions Than Answers.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2018Review
- Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment.World journal of diabetes · 2018Review
- PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.Current atherosclerosis reports · 2017Review
- Cardiovascular risk and dyslipidemia among persons living with HIV: a review.BMC infectious diseases · 2017Review
- MicroRNA-30c Mimic Mitigates Hypercholesterolemia and Atherosclerosis in Mice.The Journal of biological chemistry · 2016Article
- Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.Vascular health and risk management · 2016Review
- Prevention of cardiovascular diseases.BMC medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Barely a decade after the discovery of the gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its recognition as a key player in cholesterol metabolism, PCSK9 inhibition is now considered an exciting approach in the reduction of residual risk of cardiovascular disease. The progress from PCSK9 discovery to the development of targeted treatment has been unprecedented in terms of scale and speed. The first suggestion of a link between PCSK9 and hypercholesterolemia was published in 2003; a decade later, two meta-analyses of clinical trials comparing anti-PCSK9 treatment to placebo or ezetimibe, including >10,000 hypercholesterolemic individuals, were published. Currently, three PCSK9 inhibitors are being evaluated in clinical outcome trials and the results will determine the future of these lipid-lowering therapies by establishing their clinical efficacy in terms of cardiovascular event reduction, safety, and the consequences of prolonged exposure to very low levels of LDL-cholesterol. Irrespective of their outcomes, the exceptionally rapid development of these drugs exemplifies how novel technologies, genetic validation, and rapid clinical progression provide the tools to expedite the development of new drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.